---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-228293"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:56:06.478065+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026

## Summary
- Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.
- Phase 1 study of BDC-4182 (claudin 18.2 ISAC) showing strong immune response; protocol modified for step-up dosing.
- Initial clinical data for BDC-4182 now expected in Q3 2026, later than previously anticipated.
- Cash runway extended into 2027 via restructuring and workforce reduction.

## SEC filing metadata
- accession: 0001193125-25-228293
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/0001193125-25-228293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/bolt-20251001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-228293
- JSON: https://secwatch.observer/filing/0001193125-25-228293.json
- Plain text: https://secwatch.observer/filing/0001193125-25-228293.txt

## Source-grounded claims
- claim_id: e24d1f821560563b506195281c93c97d5282f8f5
  claim: Bolt Biotherapeutics, Inc. announced a restructuring with charges of between approximately $1.5 million to $2.0 million affecting the Company (approximately 20 employees, or approximately 50% of the Company’s workforce).
  evidence_excerpt: On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312525228293/0001193125-25-228293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.